冠心病的“生物搭桥”疗法

冠状动脉旁路移植术(CABG)和经皮冠状动脉腔内成形术(PTCA)是目前治疗冠心病的有效血管重建方法,这些方法主要靠侵入式恢复冠脉血流,存在费用高、术后再狭窄及无组织复流等问题.伴随血管新生分子机制研究的进一步深入,生物因子注射、干细胞移植和中药干预等多种疗法被应用于促进心肌血管再生和冠脉侧支循环的建立上,人们把这种通过生物因子、细胞及药物对血管生成或发生进行调控和干预,以其促进缺血心肌血管新生,增加侧支循环,改善心肌组织血流供应的方法称为“生物搭桥”.目前,治疗性血管新生已成为冠心病研究普遍关注的焦点,为冠心病治疗带来了新的希望.

"Biology Bypass"Therapy for Coronary Artery Disease

Coronary artery bypass grafting(CABG) and percutaneous coronary intervention(PCI) are the effective revascularization in clinical application at present.However,these invasive methods have many problems such as expensiveness,stenosis and no-reflow after the operation.The progresses in the understanding of the molecular mechanisms of angiogenesis have led to the identifiable therapies including biological factors injection,the stem cells transplantation and the intervention of traditional Chinese medicine for therapeutic angiogenesis and building of collateral circulation in ischemic myocardium.The method which could improve revascularization and increase collateral circulation through biological cell factors and medicine is named "biology bypass".Up to now,therapeutics angiogenesis have brought a new curable approach to coronary artery disease(CAD) and become a focus in the researches of CAD.